Always try to double check what medicine you're taking.
Always ask your pharmacist to double check what he or she is giving you.
It's harder to do that with the mail order pharmacy, but look at what they send you.
Why?
The U.S. Food and Drug Administration issued a warning and another reminder why on Wednesday when it alerted patients and pharmacists about two products -- one approved, one not - that have similar names and were mixed up, resulting in serious injury to a person who put acid in their eye when it was supposed to be used only on skin warts.
The similar names were apparently the problem in this case.
Durezol is the approved prescription medicine for treatment of inflammation and pain associated with a type of eye surgery.
Durasal is the unapproved prescription topical wart remover, which contains salicylic acid.
In its statement, the FDA said, "The FDA, as part of the drug approval process, screens proprietary names for similarities to the names of other products currently on the market; however, Durasal (salicylic acid) is an unapproved product that did not undergo FDA’s drug approval process. The agency, therefore, was not able to evaluate Durasal for potential name confusion prior to the product being marketed. Additionally, Durasal (salicylic acid) entered the market shortly after FDA approved Durezol. Elorac, Inc., the distributor of the unapproved product Durasal, has to date not responded to FDA's inquiry into removing the product from the market place. To date, Elorac has also not recalled the product in response to FDA's inquiry regarding the risk to patients."
A call to Elorac by The Inquirer was not returned on Wednesday.
- Pharmalot
- The Placebo Effect
- New York Times/Prescriptions
- Wall Street Journal/Health blog
- Financial Times
- Cafe Pharma
- Pharma Marketing
- Bio Century
- Bio Space
- Pharma Live
- Monday Morning
- In The Pipeline
- U.S. Department of Health and Human Services
- Food and Drug Administration
- Centers for Medicare and Medicaid
- Office of Inspector General, Health and Human Services
- OIG Most-wanted list of fugitives
- Centers for Disease Control and Prevention
- Securities and Exchange Commission/Edgar filings
- U.S. Attorney's Office/Eastern Pennsylvania, health-care fraud
- Clinical Trials
- Pharmaceutical Research and Manufacturers of America
- BIO
- Pennsylvania Association of Medical Suppliers
- Jersey Association of Medical Equipment Services
- Science Center
- American Health Lawyers Association
- Drug and Device Law
- Orange Book blog
- Taxpayers Against Fraud
- Adolor
- Almac
- AmerisourceBergen
- AstraZeneca
- Auxilium
- Bayer
- Celgene
- Cephalon
- Endo
- GlaxoSmithKline
- Johnson & Johnson
- Kensey Nash
- Lannett
- Merck
- Pfizer
- Roche
- Sanofi-aventis
- Shire
- Stryker
- Synthes
- Teva
- ViroPharma
- West








David Sell covers the pharmaceutical industry and related topics for The Inquirer’s Business Department. David has been a reporter and editor for more than 20 years. Contact him with tips and suggestions about news from the drug industry and the people who define an industry that touches nearly everyone and employs tens of thousands in the Philadelphia area.
Like David Sell and PhillyPharma